Compound GLP-1s: what 'uncharted territory' actually means

What did @iris_felder actually say?

Iris, 41, has lost 37 pounds on GLP-1 medication. Her insurance stopped covering it, she went off the drug for three weeks, and she says she gained "a pound a week" despite working out five days a week and hitting 160 grams of protein daily. She's now using a compounded GLP-1 from a compound pharmacy and is three injections in.

She frames the regain as evidence of an unresolved "hormonal imbalance" and mentions being a touring woman, though she doesn't specify a diagnosis. She's currently sitting around 159 pounds, down from 161, and is targeting 145-150. She's willing to share the compound pharmacy she used with followers who ask.

Does the science back up her regain experience?

Yes, this part is solidly supported. Weight regain after stopping GLP-1 medications is one of the most consistent findings in the clinical literature, and it happens fast.

The STEP 4 trial (Rubino et al., 2021, JAMA) is the most cited evidence here. Participants who stopped semaglutide after 20 weeks regained about two-thirds of their lost weight within a year. More relevant to Iris's experience, regain started within weeks of stopping, not months. A 2022 analysis in Diabetes, Obesity and Metabolism (Wilding et al.) confirmed that weight loss is largely not maintained after discontinuation, even in people who kept up lifestyle changes.

So when Iris says she was still exercising and hitting protein targets but still gaining, that tracks with what the trials show. GLP-1 receptor agonists suppress appetite and appear to affect energy regulation in ways that lifestyle changes alone don't replicate for many people. Gaining a pound a week over three weeks is aggressive but not implausible, especially if water retention and appetite return together.

What did she get wrong, and what did she get right?

She gets the core experience right. But her explanation for why it happened deserves scrutiny.

Attributing the regain to a personal "hormonal imbalance" is speculative. She says "I'm a woman, I'm a touring" (likely referring to touring schedules affecting sleep and stress, though this is unclear from the transcript). Framing it as a mystery unique to her biology undersells what the science actually shows: GLP-1 medications work partly by correcting appetite dysregulation that is common, not rare. When you stop the drug, that dysregulation returns for most people. That's not a personal hormonal mystery. That's the drug doing what it does.

She also says she moved forward with a compound pharmacy and offers to share which one in the comments. This is where things get complicated. Compounded semaglutide is not the same as FDA-approved semaglutide. The FDA has issued warnings about compounded versions, citing dosing inconsistencies and contamination risks (FDA, 2023 safety alert). Sharing a specific compounding pharmacy with 11,900 viewers without any clinical framing is worth flagging.

What should you actually know about compounded GLP-1s?

This is the section that matters most if you're considering following Iris's path.

Compounded semaglutide became widespread after Novo Nordisk's branded products (Ozempic, Wegovy) faced severe shortages. The FDA allowed compounding under shortage rules, but those rules come with conditions, and the FDA has been clear that compounded drugs are not FDA-approved and have not been evaluated for safety, efficacy, or quality in the same way. The agency issued a safety communication in 2023 specifically about compounded semaglutide, warning of dosing errors and reports of adverse events.

That doesn't mean compounded versions are useless or that everyone using them is in danger. It means the risk profile is different and less well-characterized. Telehealth platforms prescribing compounded GLP-1s are operating in a gray zone that is getting narrower as FDA oversight increases. If you're using or considering a compounded GLP-1, the prescribing clinician matters enormously. A real clinical relationship, lab monitoring, and a licensed compounding pharmacy accredited by a body like PCAB are the floor, not the ceiling.

Iris's overall message, that GLP-1s help her maintain a healthier life and that stopping them caused real setbacks, reflects what the data shows for many people. The framing around compounding is where the video needs more nuance than it delivers.